Video Library
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, share their experiences with complex treatment regimens that include oral therapy, especially as it relates to patients’ appropriate adherence to therapy.
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, discuss their perspectives on using SQ treatments for MM, including the benefits for the patients, along with a requirement for education and training for nurses with respect to delivering a high volume injection into the SQ space.
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, describe their approach to advising patients on combination therapy, especially with multidrug regimens, and counseling them on treatments that may be needed to prevent or treat therapy-related adverse events.
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, provide their perspectives on how to counsel patients on the best frontline treatment options for newly-diagnosed MM, and how this differs from relapsed/refractory MM, where individualizing treatment plans based on the patient needs and tolerability of treatment is key.
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, enumerate the major landscape shifts over the past 5 years in treating MM, including an increasing number of treatment options, the emergence of MRD testing to guide therapy, the availability of clinical trials, and the deeper, more durable responses new agents provide.
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, discuss the convenience of oral therapy along with challenges in adherence to oral therapy. Additionally, they’ll discuss the tolerability of emerging drugs, the emergence of novel adverse events with new agents, and best practices in providing supportive care for patients on these novel agents.
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, talk about the emerging treatments for MM, including monoclonal antibodies, 2nd-generation protease inhibitors, and targeted therapies. These changes pose challenges to healthcare providers struggling to keep up with these changes, but this is good news for patients with expanding treatment options.
Charise Gleason, MSN, NP-BC, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, RN-BSN, MSN, NP-C, discuss the current standard of care for both high- and low-risk patients with newly diagnosed or recurrent/refractory multiple myeloma who are initially not eligible for autologous stem-cell transplant and who subsequently become transplant-eligible.
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C discuss their approach to the care of transplant-eligible patients with multiple myeloma, particularly based on the patients' risk stratification, as well as poor-prognosis cytogenetics including those with (4,14) translocation.
As the Director for Corporate Oncology Navigation at Ballad Health, Zilipah Cruz believes that the 2018 AONN+ Annual Conference helped her understand the needs of the oncology navigators at her institution. While oncology navigators help remove the barriers that keep patients from getting the appropriate treatment, administrators like her help remove the barriers that oncology navigators face.
Canada-based registered nurse and navigator, Corrine Humby shares how visiting the Exhibit Hall at the 2018 AONN+ Annual Conference allowed her to learn about new products and services, giving her a few more tools to use and resources that she can share with her patients back home.
Financial Navigator Antoinette Whitt talks about what compelled her to start a Local Navigator Network and how it's empowered her to help other oncology navigators.
